Examination of antimicrobial effect of fluoxetine in experimental sepsis model: An in vivo study

Cakir, Ahsen; Bozalı, Kübra; Celikten, Mert; Güler, Eray Metin; Şahan, Ebru; Durdu, Bülent; Sümbül, Bilge; Koçyiğit, Abdurrahim

doi:10.1002/jbt.23240

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Batista de Andrade Neto et al, 2019;Dos Santos et al, 2020). Recent studies indicate that administration of fluoxetine in an in vitro model of sepsis inhibits the synthesis of interleukin 1 beta (IL-1β), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), myeloperoxidase (MPO) activity, monocyte chemoattractant protein -1 (MCP-1), high sensitivity C-reactive prhs-CRP, procalcitonin (PCT), lactate, and the oxidative stress index (OSI), and di-sulfide levels (Cakir et al, 2022). In a 2019 study, it was confirmed that escitalopram oxalate inhibits the growth of E. coli at a concentration of 45, 15, and 5 mM, while Bacillus subtilis is not inhibited (Valipour et al, 2019).…”

Section: Antidepressantsmentioning

confidence: 99%

Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review

et al. 2023

View full text Add to dashboard Cite

Relationship between drugs and microbiota is bilateral. Proper composition thus function of microbiota is a key to some medications used in modern medicine. However, there is also the other side of the coin. Pharmacotherapeutic agents can modify the microbiota significantly, which consequently affects its function. A recently published study showed that nearly 25% of drugs administered to humans have antimicrobial effects. Multiple antidepressants are antimicrobials,. and antibiotics with proven antidepressant effects do exist. On the other hand, antibiotics (e.g., isoniaside, minocycline) confer mental phenotype changes, and adverse effects caused by some antibiotics include neurological and psychological symptoms which further supports the hypothesis that intestinal microbiota may affect the function of the central nervous system. Here we gathered comprehensively data on drugs used in psychiatry regarding their antimicrobial properties. We believe our data has strong implications for the treatment of psychiatric entities. Nevertheless the study of ours highlights the need for more well-designed trials aimed at analysis of gut microbiota function.

show abstract

Section: Antidepressantsmentioning

confidence: 99%

Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review

et al. 2023

View full text Add to dashboard Cite

show abstract

Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?

Davies,

Teh,

Ewais

et al. 2024

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Patients with inflammatory bowel diseases (IBDs) are more likely to have depression and anxiety symptoms compared with healthy individuals and those with other chronic illnesses. Previous studies have shown a link between the microbiome composition and depression symptoms; however, many antidepressant medications have antibacterial activity confounding cross-sectional studies of these populations. Therefore, we aimed to determine whether we could detect longitudinal changes in the microbiome of a subset of patients who participated in a previously published mindfulness-based cognitive therapy (MBCT) study to improve depression symptoms in adolescents and young adults with IBD. Methods Stool samples were collected at baseline and 8 weeks (n = 24 participants, 37 total samples, 13 paired samples). During this time, some participants achieved a 50% reduction in their depression symptoms either through MBCT or treatment as usual with their mental health team (responders). The microbiome composition and function of responders were compared with participants who did not improve their depression scores (nonresponders). Depression scores were determined using the depression, anxiety, and stress score (DASS-21), and metagenomic sequencing of stool samples was performed. Results No difference in alpha diversity was found between responders and nonresponders. Beta diversity measures were similarly unchanged. Clinical features including fecal calprotectin, C-reactive protein, and serum IL-6 levels were unchanged. Conclusions In this small longitudinal study, we were not able to detect longitudinal changes in the microbiome associated with improvement in depression scores. Follow-up studies that are sufficiently powered to detect changes in the microbiome are required to confirm our results.

show abstract

Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms

Ahmed,

Jordan,

Isseroff

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Background/Objectives: The feasibility of repurposing selective serotonin reuptake inhibitors as adjunctive antibacterial agents is an area of current investigation. We sought to evaluate if fluoxetine will achieve synergistic killing with relevant antibacterial drugs against skin and soft tissue pathogens and multidrug-resistant pathogens. Methods: The MIC of fluoxetine was determined using broth microdilution for a diverse isolate collection of 21 organisms. Checkerboard experiments were then conducted using fluoxetine and clinically relevant antibacterial drugs. If fluoxetine and an anti-infective agent achieved synergy denoted by a fractional inhibitory concentration index ≤ 0.5, then the combination was further evaluated in 24 h time-killing experiments. Synergy in time-killing experiments was defined as a ≥2 log10 CFU/mL reduction in fluoxetine combined with an antibacterial agent at any point in the experiment in comparison to whichever agent in the combination resulted in the lowest bacterial counts individually. Results: The fluoxetine MICs ranged from 64 to 128 mcg/mL for Gram-positive isolates and 8–512 mcg/mL for Gram-negative organisms. Against Gram-positive isolates, vancomycin, linezolid, clindamycin, and gentamicin failed to achieve synergy in checkerboard experiments. Levofloxacin and fluoxetine were the only combination that demonstrated synergy against a Gram-positive pathogen in both checkerboard and time-killing experiments (1/6 isolates, 16.7%). Against Gram-negative organisms, the most promising combination was fluoxetine and polymyxin B, which achieved synergistic killing in both checkerboard experiments and time-killing experiments in 12/15 isolates (80%). In comparison, fosfomycin and meropenem achieved synergy in both experiments against 6/15 (40%) and 3/15 (20%) Gram-negative isolates, respectively. Conclusions: The combination of fluoxetine and polymyxin B may be a potential strategy for combatting difficult-to-treat Gram-negative pathogens.

show abstract

Examination of antimicrobial effect of fluoxetine in experimental sepsis model: An in vivo study

Cited by 3 publications

References 27 publications

Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review

Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review

Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?

Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms

Contact Info

Product

Resources

About